No Data
Nomura HD, Chugai Pharmaceutical, Fujitsu, Canon Inc-Spons Adr (24th)
※The above Calendar is just a plan and may change due to the company's circumstances. --------------------------------------- April 24 (Thursday) <2211> Fujika <2664> Kawachi Drug <2737> Tomen Deba <3231> Nomura Real Estate HD <3593> Hogi Medi <3891> Advanced Paper <4307> NRI <4519> Chugai Pharmaceutical <4765>
Daiichi Sankyo (ADR) (DSNKY.US) will release its Earnings Reports on April 25.
$Daiichi Sankyo (ADR) (DSNKY.US)$ will release its Earnings Reports on April 25, and investors are advised to pay attention. How was the performance previously? $Daiichi Sankyo (ADR) (DSNKY.US)$ reported a revenue of 484.84 billion yen and a Net income of 61.928 billion yen in Q3 2025, with an EPS of 32.79 yen. For Q4 2024, the revenue was 428.419 billion yen, with a Net income of 36.914 billion yen and an EPS of 19.37 yen. The accounting standards used for the above data are NonUS_GAAP. Futubull reminder: 1. Listed on Hong Kong stocks and U.S. stocks.
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients
AstraZeneca Says Breast Cancer Combination Therapy Shows Improvement in Progression-Free Survival
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial
Express News | AstraZeneca And Daiichi Sankyo's ENHERTU Plus Pertuzumab Demonstrates Statistically Significant PFS Benefit In Phase 3 Trial
